HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

52.050

+1.6503.27%

Volume:698.10K

Turnover:36.09M

Market Cap:10.36B

PE:-36.84

High:52.350

Open:50.650

Low:50.150

Close:50.400

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.43

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.413

ROE:-51.55%

ROA:-12.87%

PB:9.53

PE(LYR):-36.84

PS:41.60

Loading ...

Overview Company News Filings

Hong Kong Stock Alert | LEADS BIOLABS-B (09887) Opens Nearly 3% Higher as PD-L1/4-1BB Bispecific Antibody Achieves Dual Breakthroughs in Response Rate and PFS Rate for First-Line NSCLC Treatment

Movement Alert｜LEADS BIOLABS-B Rises 6.18% in Regular Trading, Positive Phase II Data for Welixin Presented at WCLC Boosts Market Confidence

Nanjing Leads Biolabs Presents Data from Lung Cancer Drug Trial at Global Conference

MT Newswires Live

LEADS BIOLABS-B (09887) Presents Updated Phase II Data on Vilixine® (Oritasomimab, PD-L1/4-1BB Bispecific) Combined with Chemotherapy as First-Line NSCLC Treatment at WCLC 2026 Oral Session

Leads Biolabs posts 71% overall response rate for bispecific antibody LBL-024 in first-line NSCLC Phase II trial

Bulletin Express

Movement Alert｜LEADS BIOLABS-B Falls 5.07% in Regular Trading, Competitor Data at WCLC Intensifies Market Uncertainty Ahead of Key Data Update

LEADS BIOLABS-B (09887) Sees HK$669 Million in Deposited Securities; Major Shareholder Moves 9.71 Million Shares to Morgan Stanley HK

LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained

Leads Biolabs Records Stable Share Structure in August 2026; Public Float Fully Compliant

Bulletin Express

Movement Alert｜LEADS BIOLABS-B Falls 5.05% in Regular Trading, Interim Net Loss Widens Over 33% Year-on-Year

LEADS BIOLABS-B (09887) Announces Interim Results: Net Loss Widens 33.38% to Approximately RMB 222 Million

Nanjing Leads Biolabs FY26 H1 Loss Widens 33.4% to RMB 221.93 Million; Revenue Swings to RMB 35.97 Million

Nanjing Leads Biolabs Co Ltd - Hy Loss Attributable Rmb221.9 Mln

THOMSON REUTERS

Movement Alert｜LEADS BIOLABS-B Falls 5.03% in Regular Trading, Trading at HK$70.85

Nanjing Leads Rises on Clinical Study Progress on Cancer Treatment Drug

Leads Biolabs Advances Opamtistomig Phase II First-Line ESCC Trial into Expansion Stage

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Phase Ii Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

THOMSON REUTERS

Hong Kong Stock Flash | LEADS BIOLABS-B (09887) Surges Over 5% in Morning Trade as Phase II Trial for First-Line ESCC Advances to Expansion Stage

Movement Alert｜LEADS BIOLABS-B Rises 5.14% in Regular Trading, Phase II ESCC Study Enters Expansion Stage

LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/09887/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":52.05,"timestamp":1790755707009,"preClose":50.4,"halted":0,"volume":698100,"delay":0,"changeRate":0.03273809523809521,"floatShares":198000000,"shares":199000000,"eps":-1.4130070072740684,"marketStatus":"Closed National Day","change":1.65,"latestTime":"09-30 16:08:27","open":50.65,"high":52.35,"low":50.15,"amount":36092305,"amplitude":0.043651,"askPrice":52.05,"askSize":5900,"bidPrice":52,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-1.6080860540336945,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":50.4,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":0.42945670677487274,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.413007,"volumeRatio":0.42945670677487274,"shares":199000000,"dividePrice":0,"high":52.35,"amplitude":0.043651,"preClose":50.4,"low":50.15,"week52Low":44.72,"pbRate":"9.53","psRate":"41.60","week52High":97.5,"institutionHeld":0,"latestPrice":52.05,"committee":-0.594595,"eps":-1.4130070072740684,"divideRate":0,"volume":698100,"delay":0,"ttmEps":-1.6080860540336945,"open":50.65,"prevYearClose":51,"prevWeekClose":52.3,"prevMonthClose":52.05,"prevQuarterClose":52.05,"fiveDayClose":56.2,"twentyDayClose":66.95,"sixtyDayClose":49.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1789574400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-30","current":-32.365967,"percent":0.931271,"low":-76.458084,"twenty":-45.103722,"median":-39.792054,"eighty":-34.499578,"high":-30.202688,"avg":-41.718875,"sd":9.610754,"marketCap":10156079280},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-11","current":-37.6607,"twenty":-45.564242,"median":-39.940552,"eighty":-34.761336,"marketCap":11746320320},{"date":"2026-09-18","current":-34.8313,"twenty":-45.532372,"median":-39.845109,"eighty":-34.761336,"marketCap":10878029200},{"date":"2026-09-25","current":-32.738215,"twenty":-45.269178,"median":-39.795685,"eighty":-34.653517,"marketCap":10204859680},{"date":"2026-09-30","current":-32.521052,"twenty":-45.103722,"median":-39.792054,"eighty":-34.499578,"marketCap":10156079280}],"updateTime":1790844022539},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1137098971","title":"Hong Kong Stock Alert | LEADS BIOLABS-B (09887) Opens Nearly 3% Higher as PD-L1/4-1BB Bispecific Antibody Achieves Dual Breakthroughs in Response Rate and PFS Rate for First-Line NSCLC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1137098971","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137098971?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:36","pubTimestamp":1789436186,"startTime":"0","endTime":"0","summary":"Shares of LEADS BIOLABS-B (09887) opened nearly 3% higher on Monday, with the stock last trading up 2.44% at HK$63, reflecting a turnover of HK$4.586 million. The surge comes on the heels of the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK4585","KCAI","VXUS","09887","LU1169590202.USD","BK1161","LU1169589451.USD","PD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176880659","title":"Movement Alert｜LEADS BIOLABS-B Rises 6.18% in Regular Trading, Positive Phase II Data for Welixin Presented at WCLC Boosts Market Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1176880659","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176880659?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:31","pubTimestamp":1789435919,"startTime":"0","endTime":"0","summary":"On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.On the news front, the company announced on September 14...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CLSA Lifts LEADS BIOLABS-B Target to 116.9 HKD on Positive NSCLC Data","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667550668","title":"Nanjing Leads Biolabs Presents Data from Lung Cancer Drug Trial at Global Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2667550668","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667550668?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:08","pubTimestamp":1789384099,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs  orally presented updated data from a phase II study of its LBL-024 at the 2026 World Conference on Lung Cancer.The trial tested the drug in combination with chemotherapy as first-line treatment for patients with non-small cell lung cancer, according to a Monday bourse disclosure.The updated data demonstrated high response rates, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180846137","title":"LEADS BIOLABS-B (09887) Presents Updated Phase II Data on Vilixine® (Oritasomimab, PD-L1/4-1BB Bispecific) Combined with Chemotherapy as First-Line NSCLC Treatment at WCLC 2026 Oral Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1180846137","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180846137?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:27","pubTimestamp":1789378050,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has disclosed via an official announcement that updated results from its Phase II clinical trial evaluating Vilixine® (Oritasomimab, a PD-L1/4-1BB bispecific antibody) in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","HK0000500386.USD","BK1161","LU1169590202.USD","HK0000252152.HKD","PD","09887","HK0000252160.HKD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108838914","title":"Leads Biolabs posts 71% overall response rate for bispecific antibody LBL-024 in first-line NSCLC Phase II trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1108838914","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108838914?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:23","pubTimestamp":1789377798,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported updated Phase II results for its PD-L1/4-1BB bispecific antibody LBL-024 (Opamtistomig) combined with chemotherapy as an initial treatment for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122776273","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.07% in Regular Trading, Competitor Data at WCLC Intensifies Market Uncertainty Ahead of Key Data Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1122776273","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122776273?lang=en_us&edition=fundamental","pubTime":"2026-09-14 09:48","pubTimestamp":1789350537,"startTime":"0","endTime":"0","summary":"On September 14, LEADS BIOLABS-B fell 5.07% in regular trading, trading at 57.45 HKD/share, with turnover of approximately HKD 18.55 million. The decline comes amid heightened competitive dynamics...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LEADS BIOLABS-B Falls as WCLC Data Update Looms","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119471164","title":"LEADS BIOLABS-B (09887) Sees HK$669 Million in Deposited Securities; Major Shareholder Moves 9.71 Million Shares to Morgan Stanley HK","url":"https://stock-news.laohu8.com/highlight/detail?id=1119471164","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119471164?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:08","pubTimestamp":1788484095,"startTime":"0","endTime":"0","summary":"A recent filing with the Hong Kong Stock Exchange revealed a notable position change for LEADS BIOLABS-B (09887) on September 3rd. The company's total deposited market value reached HK$669 million,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","161027","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180112319","title":"LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1180112319","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180112319?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:12","pubTimestamp":1788340334,"startTime":"0","endTime":"0","summary":"CLSA has released a research report indicating that LEADS BIOLABS-B (09887) generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102176356","title":"Leads Biolabs Records Stable Share Structure in August 2026; Public Float Fully Compliant","url":"https://stock-news.laohu8.com/highlight/detail?id=1102176356","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102176356?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:02","pubTimestamp":1788339763,"startTime":"0","endTime":"0","summary":"For the month ended 31 August 2026, Nanjing Leads Biolabs Co., Ltd. reported no movements in either authorised or issued share capital, underscoring a steady equity base throughout the period....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136017385","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.05% in Regular Trading, Interim Net Loss Widens Over 33% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1136017385","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136017385?lang=en_us&edition=fundamental","pubTime":"2026-09-01 14:12","pubTimestamp":1788243139,"startTime":"0","endTime":"0","summary":"On September 1, LEADS BIOLABS-B fell 5.05% in regular trading, trading at HK$68.55/share, with turnover of HK$143 million. The decline came after the company released its interim results on August...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LEADS BIOLABS-B Drops as Net Loss Widens 33%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161064979","title":"LEADS BIOLABS-B (09887) Announces Interim Results: Net Loss Widens 33.38% to Approximately RMB 222 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1161064979","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161064979?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:40","pubTimestamp":1788165619,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has unveiled its interim results for the 2026 fiscal year, recording revenue of RMB 35.969 million. Research and development expenses surged by 44.92% year-on-year to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073726","title":"Nanjing Leads Biolabs FY26 H1 Loss Widens 33.4% to RMB 221.93 Million; Revenue Swings to RMB 35.97 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073726","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073726?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:32","pubTimestamp":1788165161,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs FY26 H1 loss widens 33.4% to RMB 221.93 million; revenue swings to RMB 35.97 millionNanjing Leads Biolabs posted revenue of RMB 35.97 million, compared with no revenue a year ear","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL9ZD8wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073742","title":"Nanjing Leads Biolabs Co Ltd - Hy Loss Attributable Rmb221.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073742?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:32","pubTimestamp":1788165150,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161283999","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.03% in Regular Trading, Trading at HK$70.85","url":"https://stock-news.laohu8.com/highlight/detail?id=1161283999","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161283999?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:59","pubTimestamp":1787727540,"startTime":"0","endTime":"0","summary":"On August 26, LEADS BIOLABS-B fell 5.03% in regular trading, trading at HK$70.85/share, with turnover of HK$111 million.Within the Biotechnology sector where LEADS BIOLABS-B belongs, peer stocks...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662531786","title":"Nanjing Leads Rises on Clinical Study Progress on Cancer Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662531786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662531786?lang=en_us&edition=fundamental","pubTime":"2026-08-25 13:43","pubTimestamp":1787636594,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads rises on clinical study progress on cancer treatment drug** Shares of Nanjing Leads Biolabs9887.HKjump 9.2% to HK$75.4, their biggest intraday pct gain since July 15** The China-based oncology and autoimmune therapies developer says Phase II clinical study of its drug candidate LBL-024 as a first-line treatment for patients with metastatic esophageal squamous cell carcinoma has completed the safety lead-in stage and has advanced to the combination treatmentexpansion stage** LBL-024 has demonstrated a favourable safety and tolerability profile in about 800 patients treated to date, supporting its development as a potential next-generation immuno-oncology backbone therapy, says Nanjing Leads** YTD, stock up 46.2%, Hang Seng Biotech Index.HSBIOup 11.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M047:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200258","title":"Leads Biolabs Advances Opamtistomig Phase II First-Line ESCC Trial into Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662200258?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624721,"startTime":"0","endTime":"0","summary":"Leads Biolabs advances Opamtistomig Phase II first-line ESCC trial into expansion stageNanjing Leads Biolabs moved its Phase II study of Opamtistomig into an expansion stage for first-line esophageal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL2FJpxz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","BK4588","NDAQ","IE00BQXX3F31.USD","HK0000252160.HKD","HK0000500386.USD","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014005.SGD","09887","BK1161","SG9999014021.USD","IE00BGHQF748.EUR","BCDF","LU2210149790.SGD","HK0000252152.HKD","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004752","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Phase Ii Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662004752?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7XQSTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131567775","title":"Hong Kong Stock Flash | LEADS BIOLABS-B (09887) Surges Over 5% in Morning Trade as Phase II Trial for First-Line ESCC Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131567775","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131567775?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:16","pubTimestamp":1787624183,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) shares climbed more than 5% during Tuesday morning trading, last up 4.42% at HK$72.10 with turnover reaching HK$33.55 million.The company announced that its self-developed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","VXUS","BK1161","BK4585","HK0000252160.HKD","HK0000500386.USD","BK4588","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163673761","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.14% in Regular Trading, Phase II ESCC Study Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1163673761","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163673761?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:55","pubTimestamp":1787622946,"startTime":"0","endTime":"0","summary":"On August 25, LEADS BIOLABS-B rose 5.14% in regular trading, trading at HK$72.4/share, with turnover of approximately HK$28.4 million. The stock gained on news that its core drug candidate Vilixin...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Surges on Vilixin ESCC Phase II Expansion","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121426329","title":"LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1121426329","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121426329?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:00","pubTimestamp":1787612419,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the Phase II clinical study of its self-developed investigational drug Vilitrin (Opasotiumumab, a PD-L1/4-1BB bispecific antibody, LBL-024) for the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","PD","LU1169590202.USD","BK4023","HK0000252152.HKD","LU1169589451.USD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":145,"code":"91000000","status":"200"}]}}